Next Article in Journal
Targeting Inflammasome Activation in COVID-19: Delivery of RNA Interference-Based Therapeutic Molecules
Next Article in Special Issue
Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center
Previous Article in Journal
Prostaglandin F2 and EP2 Agonists Exert Different Effects on 3D 3T3-L1 Spheroids during Their Culture Phase
Previous Article in Special Issue
Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma
Article

Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy

1
Department of Health Sciences, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, Italy
2
Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy
3
Department of Basic Medical Sciences, Neuroscience and Sense Organs, Section of Respiratory Disease, University “Aldo Moro” of Bari, 70121 Bari, Italy
4
Division of Allergy and Clinical Immunology, Department of Medicine, “Santa Maria della Speranza” Hospital, 84091 Battipaglia, Italy
5
Allergology and Pulmonology Unit, Provincial Outpatient Center of Palermo, 90100 Palermo, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Hiroshi Wakao
Biomedicines 2021, 9(12), 1822; https://doi.org/10.3390/biomedicines9121822
Received: 17 October 2021 / Revised: 28 November 2021 / Accepted: 30 November 2021 / Published: 3 December 2021
(This article belongs to the Special Issue Molecular Targets for Biological Therapies of Severe Asthma)
Background. The wide availability of monoclonal antibodies for the add-on therapy of severe asthma currently allows for the personalization of biologic treatment by selecting the most appropriate drug for each patient. However, subjects with overlapping allergic and eosinophilic phenotypes can be often eligible to more than one biologic, so that the first pharmacologic choice can be quite challenging for clinicians. Within such a context, the aim of our real-life investigation was to verify whether allergic patients with severe eosinophilic asthma, not adequately controlled by an initial biologic treatment with omalizumab, could experience better therapeutic results from a pharmacologic shift to benralizumab. Patients and methods. Twenty allergic patients with severe eosinophilic asthma, unsuccessfully treated with omalizumab and then switched to benralizumab, were assessed for at least 1 year in order to detect eventual changes in disease exacerbations, symptom control, oral corticosteroid intake, lung function, and blood eosinophils. Results. In comparison to the previous omalizumab therapy, after 1 year of treatment with benralizumab our patients experienced significant improvements in asthma exacerbation rate (p < 0.01), rescue medication need (p < 0.001), asthma control test (ACT) score (p < 0.05), forced expiratory volume in the first second (FEV1) (p < 0.05), and blood eosinophil count (p < 0.0001). Furthermore, with respect to the end of omalizumab treatment, the score of sino-nasal outcome test-22 (SNOT-22) significantly decreased after therapy with benralizumab (p < 0.05). Conclusion. The results of this real-life study suggest that the pharmacologic shift from omalizumab to benralizumab can be a valuable therapeutic approach for allergic patients with severe eosinophilic asthma, not adequately controlled by anti-IgE treatment. View Full-Text
Keywords: severe asthma; allergy; eosinophils; omalizumab; benralizumab; switching severe asthma; allergy; eosinophils; omalizumab; benralizumab; switching
Show Figures

Figure 1

MDPI and ACS Style

Pelaia, C.; Crimi, C.; Nolasco, S.; Carpagnano, G.E.; Brancaccio, R.; Buonamico, E.; Campisi, R.; Gagliani, C.; Patella, V.; Pelaia, G.; Valenti, G.; Crimi, N. Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy. Biomedicines 2021, 9, 1822. https://doi.org/10.3390/biomedicines9121822

AMA Style

Pelaia C, Crimi C, Nolasco S, Carpagnano GE, Brancaccio R, Buonamico E, Campisi R, Gagliani C, Patella V, Pelaia G, Valenti G, Crimi N. Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy. Biomedicines. 2021; 9(12):1822. https://doi.org/10.3390/biomedicines9121822

Chicago/Turabian Style

Pelaia, Corrado, Claudia Crimi, Santi Nolasco, Giovanna E. Carpagnano, Raffaele Brancaccio, Enrico Buonamico, Raffaele Campisi, Claudia Gagliani, Vincenzo Patella, Girolamo Pelaia, Giuseppe Valenti, and Nunzio Crimi. 2021. "Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy" Biomedicines 9, no. 12: 1822. https://doi.org/10.3390/biomedicines9121822

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop